|
1
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cree IA: Cancer biology. Methods Mol Biol.
731:1–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ebell MH, Culp MB and Radke TJ: A
systematic review of symptoms for the diagnosis of ovarian cancer.
Am J Prev Med. 50:384–394. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mozzetti S, Ferlini C, Concolino P,
Filippetti F, Raspaglio G, Prislei S, Gallo D, Martinelli E,
Ranelletti FO, Ferrandina G and Scambia G: Class III β-Tubulin
overexpression is a prominent mechanism of paclitaxel resistance in
ovarian cancer patients. Clin Cancer Res. 11:298–305.
2005.PubMed/NCBI
|
|
5
|
GBD 2015 Mortality and Causes of Death
Collaborators: Global, regional, and national life expectancy,
all-cause mortality, and cause-specific mortality for 249 causes of
death, 1980–2015: A systematic analysis for the global burden of
disease study 2015. Lancet. 388:1459–1544. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McGuire S: World Cancer Report 2014.
Geneva, Switzerland: World Health Organization, International
Agency for Research on Cancer, WHO Press, 2015. Adv Nutr.
7:418–419. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mei L, Hu Q, Peng J, Ruan J, Zou J, Huang
Q, Liu S and Wang H: Phospho-histone H2AX is a diagnostic and
prognostic marker for epithelial ovarian cancer. Int J Clin Exp
Pathol. 8:5597–5602. 2015.PubMed/NCBI
|
|
8
|
Yamamoto S, Tsuda H, Honda K, Onozato K,
Takano M, Tamai S, Imoto I, Inazawa J, Yamada T and Matsubara O:
Actinin-4 gene amplification in ovarian cancer: A candidate
oncogene associated with poor patient prognosis and tumor
chemoresistance. Mod Pathol. 22:499–507. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Walsh CS, Ogawa S, Karahashi H, Scoles DR,
Pavelka JC, Tran H, Miller CW, Kawamata N, Ginther C, Dering J, et
al: ERCC5 is a novel biomarker of ovarian cancer prognosis. J Clin
Oncol. 26:2952–2958. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hashimoto T, Yanaihara N, Okamoto A,
Nikaido T, Saito M, Takakura S, Yasuda M, Sasaki H, Ochiai K and
Tanaka T: Cyclin D1 predicts the prognosis of advanced serous
ovarian cancer. Exp Ther Med. 2:213–219. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dai J, Wei RJ, Li R, Feng JB, Yu YL and
Liu PS: A study of CCND1 with epithelial ovarian cancer cell
proliferation and apoptosis. Eur Rev Med Pharmacol Sci.
20:4230–4235. 2016.PubMed/NCBI
|
|
12
|
Ge L, Li N, Liu M, Xu NZ, Wang MR and Wu
LY: Copy number variations of neurotrophic tyrosine receptor kinase
3 (NTRK3) may predict prognosis of ovarian cancer. Medicine
(Baltimore). 96:e76212017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ayhan A, Kuhn E, Wu RC, Ogawa H,
Bahadirli-Talbott A, Mao TL, Sugimura H, Shih IM and Wang TL: CCNE1
copy-number gain and overexpression identify ovarian clear cell
carcinoma with a poor prognosis. Mod Pathol. 30:297–303. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gonzalez VM, Fuertes MA, Alonso C and
Perez JM: Is cisplatin-induced cell death always produced by
apoptosis? Mol Pharmacol. 59:657–663. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yakirevich E, Sabo E, Naroditsky I, Sova
Y, Lavie O and Resnick MB: Multidrug resistance-related phenotype
and apoptosis-related protein expression in ovarian serous
carcinomas. Gynecol Oncol. 100:152–159. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Norouzi-Barough L, Sarookhani MR, Sharifi
M, Moghbelinejad S, Jangjoo S and Salehi R: Molecular mechanisms of
drug resistance in ovarian cancer. J Cell Physiol. 233:4546–4562.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lisowska KM, Olbryt M, Dudaladava V,
Pamuła-Piłat J, Kujawa K, Grzybowska E, Jarząb M, Student S,
Rzepecka IK, Jarząb B and Kupryjańczyk J: Gene expression analysis
in ovarian cancer-faults and hints from DNA microarray study. Front
Oncol. 4:62014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bolstad BM, Irizarry RA, Astrand M and
Speed TP: A comparison of normalization methods for high density
oligonucleotide array data based on variance and bias.
Bioinformatics. 19:185–193. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Greenman CD, Bignell G, Butler A, Edkins
S, Hinton J, Beare D, Swamy S, Santarius T, Chen L, Widaa S, et al:
PICNIC: An algorithm to predict absolute allelic copy number
variation with microarray cancer data. Biostatistics. 11:164–175.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Harrow J, Frankish A, Gonzalez JM,
Tapanari E, Diekhans M, Kokocinski F, Aken BL, Barrell D, Zadissa
A, Searle S, et al: GENCODE: The reference human genome annotation
for The ENCODE Project. Genome Res. 22:1760–1774. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Parrish RS and Spencer HJ III: Effect of
normalization on significance testing for oligonucleotide
microarrays. J Biopharm Stat. 14:575–589. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang P, Wang Y, Hang B, Zou X and Mao JH:
A novel gene expression-based prognostic scoring system to predict
survival in gastric cancer. Oncotarget. 7:55343–55351.
2016.PubMed/NCBI
|
|
24
|
Bao Z, Zhang W and Dong D: A potential
prognostic lncRNA signature for predicting survival in patients
with bladder urothelial carcinoma. Oncotarget. 8:10485–10497. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zeng JH, Liang L, He RQ, Tang RX, Cai XY,
Chen JQ, Luo DZ and Chen G: Comprehensive investigation of a novel
differentially expressed lncRNA expression profile signature to
assess the survival of patients with colorectal adenocarcinoma.
Oncotarget. 8:16811–16828. 2017.PubMed/NCBI
|
|
26
|
Jager KJ, van Dijk PC, Zoccali C and
Dekker FW: The analysis of survival data: The Kaplan-Meier method.
Kidney Int. 74:560–565. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Eng KH, Schiller E and Morrell K: On
representing the prognostic value of continuous gene expression
biomarkers with the restricted mean survival curve. Oncotarget.
6:36308–36318. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smyth GK: Limma: Linear models for
microarray data. Bioinformatics and Computational Biology Solutions
Using R and Bioconductor. Gentleman R, Carey V, Dudoit S, Irizarry
R and Huber W: Springer; New York, NY: pp. 397–420. 2005,
View Article : Google Scholar
|
|
29
|
Ackermann M and Strimmer K: A general
modular framework for gene set enrichment analysis. BMC
Bioinformatics. 10:472009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Amos LA: The tektin family of
microtubule-stabilizing proteins. Genome Biol. 9:2292008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hanafusa T, Mohamed AE, Domae S, Nakayama
E and Ono T: Serological identification of Tektin5 as a
cancer/testis antigen and its immunogenicity. BMC Cancer.
12:5202012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Noetzel E, Rose M, Sevinc E, Hilgers RD,
Hartmann A, Naami A, Knüchel R and Dahl E: Intermediate filament
dynamics and breast cancer: Aberrant promoter methylation of the
Synemin gene is associated with early tumor relapse. Oncogene.
29:4814–4825. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ho CC, Ho HC, Liu YH, Pei RJ, Cheng CC,
Lee KY, Yeh KT and Lai YS: Altered synemin could affect the
organization of intermediate filament in human hepatocellular
carcinoma. J Med. 35:171–180. 2004.PubMed/NCBI
|
|
34
|
Staff AC, Bock AJ, Becker C, Kempf T,
Wollert KC and Davidson B: Growth differentiation factor-15 as a
prognostic biomarker in ovarian cancer. Gynecol Oncol. 118:237–243.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bock AJ, Stavnes HT, Kempf T, Tropè CG,
Berner A, Davidson B and Staff AC: Expression and clinical role of
growth differentiation factor-15 in ovarian carcinoma effusions.
Int J Gynecol Cancer. 20:1448–1455. 2010.PubMed/NCBI
|
|
36
|
Griner SE, Joshi JP and Nahta R: Growth
differentiation factor 15 stimulates rapamycin-sensitive ovarian
cancer cell growth and invasion. Biochem Pharmacol. 85:46–58. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tykwinska K, Lauster R, Knaus P and
Rosowski M: Growth and differentiation factor 3 induces expression
of genes related to differentiation in a model of cancer stem cells
and protects them from retinoic acid-induced apoptosis. PLoS One.
8:e706122013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li Q, Ling Y and Yu L: GDF3 inhibits the
growth of breast cancer cells and promotes the apoptosis induced by
Taxol. J Cancer Res Clin Oncol. 138:1073–1079. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ota K, Ito K, Akahira J, Sato N, Onogawa
T, Moriya T, Unno M, Abe T, Niikura H, Takano T and Yaegashi N:
Expression of organic cation transporter SLC22A16 in human
epithelial ovarian cancer: A possible role of the adriamycin
importer. Int J Gynecol Pathol. 26:334–340. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ota K, Akahira JI, Sato N, Moriya T, Unno
M, Abe T, Ito K and Yaegashi N: Expression of the organic cation
transporter SLC22A16 can be a feature of human epithelial ovarian
cancers with different histological type. J Clin Oncol.
23:51312005. View Article : Google Scholar
|
|
41
|
Chen L, Hong C, Chen EC, Yee SW, Xu L,
Almof EU, Wen C, Fujii K, Johns SJ, Stryke D, et al: Genetic and
epigenetic regulation of the organic cation transporter 3, SLC22A3.
Pharmacogenomics J. 13:110–120. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yokoo S, Masuda S, Yonezawa A, Terada T,
Katsura T and Inui K: Significance of organic cation transporter 3
(SLC22A3) expression for the cytotoxic effect of oxaliplatin in
colorectal cancer. Drug Metab Dispos. 36:2299–2306. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Tan DS, Rothermundt C, Thomas K, Bancroft
E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB and Gore
ME: ‘BRCAness’ syndrome in ovarian cancer: A case-control study
describing the clinical features and outcome of patients with
epithelial ovarian cancer associated with BRCA1 and BRCA2
mutations. J Clin Oncol. 26:5530–5536. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gallagher DJ, Konner JA, Bell-McGuinn KM,
Bhatia J, Sabbatini P, Aghajanian CA, Offit K, Barakat RR, Spriggs
DR and Kauff ND: Survival in epithelial ovarian cancer: A
multivariate analysis incorporating BRCA mutation status and
platinum sensitivity. Ann Oncol. 22:1127–1132. 2011. View Article : Google Scholar : PubMed/NCBI
|
